Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 1.2%

Enlivex Therapeutics Ltd. (NASDAQ:ENLVGet Rating) traded up 1.2% during mid-day trading on Monday . The stock traded as high as $4.28 and last traded at $4.20. 35,577 shares were traded during mid-day trading, an increase of 33% from the average session volume of 26,684 shares. The stock had previously closed at $4.15.

Enlivex Therapeutics Trading Up 1.2 %

The company’s fifty day simple moving average is $4.29 and its 200 day simple moving average is $4.54. The stock has a market capitalization of $77.33 million, a P/E ratio of -2.69 and a beta of 1.03.

Enlivex Therapeutics (NASDAQ:ENLVGet Rating) last issued its quarterly earnings data on Monday, December 5th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). Equities research analysts predict that Enlivex Therapeutics Ltd. will post -1.64 earnings per share for the current year.

Institutional Trading of Enlivex Therapeutics

A number of large investors have recently modified their holdings of the business. UBS Group AG raised its stake in Enlivex Therapeutics by 73.4% in the third quarter. UBS Group AG now owns 31,871 shares of the company’s stock valued at $136,000 after purchasing an additional 13,490 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Enlivex Therapeutics by 87.0% in the 1st quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock worth $34,000 after buying an additional 2,867 shares during the last quarter. Jane Street Group LLC raised its position in shares of Enlivex Therapeutics by 89.6% during the 1st quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock valued at $294,000 after buying an additional 24,807 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Enlivex Therapeutics during the 1st quarter worth $68,000. Institutional investors own 1.82% of the company’s stock.

Enlivex Therapeutics Company Profile

(Get Rating)

Enlivex Therapeutics Ltd. is a clinical stage macrophage reprogramming immunotherapy company, which develops Allocetra,a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.

Recommended Stories

Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.